To develop a reliable, High-performance Liquid Chromatography technique for the simultaneous determination of a Fixed-Dose Combination of hydrochlorothiazide, amlodipine besylate, and telmisartan. The concepts of Green Analytical Chemistry and Analytical Quality by Design are combined in this work. For optimal results, Shim-pack C18 (4.6 × 250mm, 5µm particle size) was utilized. With an injection volume of 20 µL, a gradient of isopropanol: acetate buffer (0.1M, pH 5.8) as a buffer, at a flow rate of 1.075mL/min, and UV detection at 324nm, the mobile phase was composed. The retention times for hydrochlorothiazide (HCT), amlodipine besylate (AML), and telmisartan (TEL) were found to be 3.192, 4.515, and 5.097min, respectively. All parameters, including relative standard deviation, accuracy, precision, linearity, robustness, and specificity, were examined and found to be less than 2% for the proposed approach. Dong's algorithm computations have identified and verified the areas where the method's optimization is carried out in the design space allotted to the developed method for estimating these drugs in combination dose forms. The developed method was validated and found to be successful in identifying the three drugs in commercially available tablets. In addition to this the method sustainability was assessed with a comprehensive multi-parameter evaluation adopting various sustainability assessment tools including carbon footprint estimation and mobile phase greenness assessment using the Green Environmental Assessment and Rating for Solvents (GEARS), and environmental impact indices such as the Red Analytical Performance Index (RAPI), Click Analytical Chemistry Index (CACI), Blue Applicability Grade Index (BAGI), Modified Green Analytical Procedure Index (MoGAPI), Analytical GREEnness prep (AGREEprep), Analytical Green Star Area (AGSA), and RGBfast. The collective outcomes of these assessments demonstrated that the proposed method is environmentally benign, as it employs fewer hazardous chemicals, generates reduced waste, and requires lower energy consumption.

Polymyxin B (PMB) is widely used as a last-line antibiotic for treating serious infections caused by multidrug-resistant Gram-negative bacteria. However, its clinical use is restricted by significant nephrotoxicity, which limits dosing flexibility and compromises therapeutic efficacy. Objective The aim of this study was to evaluate the potential nephroprotective effects of telmisartan (TMS) and nicorandil (NIC) in rats treated with polymyxin B (PMB). Methods Rats were randomly allocated into four groups. Normal control; PMB (12 mg/kg/day, S.C. for one week); TMS + PMB (10 mg/kg/day TMS orally (p.o.) for two weeks); and NIC + PMB (3 mg/kg/day NIC, i.p. for two weeks). Both drugs were administered one hour prior to PMB for one week and continued for an additional week. At the end of the treatment period, animals were anesthetized, and blood and kidney tissue samples were collected for histological and immunohistochemical analyses, as well as assessments of renal function, oxidative stress markers, mitochondrial dysfunction, endoplasmic reticulum stress, and apoptotic biomarkers. Results The findings demonstrated that both telmisartan and nicorandil significantly improved renal function and attenuated oxidative stress, mitochondrial dysfunction, ER stress, and apoptosis-related markers. Histopathological findings supported these results. Conclusion The renoprotective effects of telmisartan and nicorandil were mediated through modulation of the Nrf2/NQO1 antioxidant pathway and FAS/FASL apoptotic signaling, along with downregulation of renal expression of p53, cytochrome c, and caspase-3. These observations clearly indicate the protective role of both agents against PMB-induced nephrotoxicity.

This work describes the development of a voltammetric method for the determination of telmisartan (TEL) employing an anodically pretreated boron-doped diamond electrode (AP-BDDE). In this electrode, TEL presented an irreversible peak at +1.33 V (vs. Ag/AgCl), which was associated with its oxidation involving two electrons and two protons. From the combination of electrochemistry and NMR spectroscopy data, it was possible to propose for the first time the reaction of oxidation for the TEL molecule onto the BDDE. Parameters recommended by validation guidelines were evaluated to validate the proposed method. Using differential pulse voltammetry, a linear plot was obtained for TEL in the concentration range 10-109 nmol L-1 in acetate buffer (pH 5.0), with a limit of detection of 0.16 nmol L-1. The selectivity of the methods was assessed against urine and water interferers, showing relative standard deviation values below 8%. The proposed method was successfully applied to pharmaceutical, environmental, and biological samples, exhibiting profiles consistent with green analytical chemistry, as confirmed by an assessment using the AGREE approach from the literature.

Fipronil (FIP), as a broad-spectrum pesticide, contributes to adverse reproductive effects. Thus, our study aimed to investigate the effect of telmisartan (TEL) as a selective angiotensin 1 receptor (AT1R) blocker on mitochondrial damage induced by FIP intoxication in male rats. Forty healthy male albino rats were allocated into 4 groups (10/ group): the control group, the TEL group received TEL (10 mg/kg b.wt.), the FIP group received FIP (1/10 of the LD50 of 97 mg/kg b.wt.), and the FIP + TEL cotreated group. All treatments were taken orally for 60 days. Before the experiment, in-silico assessments of FIP and TEL were done. FIP administration diminished relative testicular weight, sperm count, and motility, besides significantly increasing sperm abnormalities (p < 0.05). Biochemically, FIP treatment reduced considerably (p < 0.05) serum testosterone, luteinizing hormone (LH), and follicular-stimulating hormone (FSH) levels related to control animals. Furthermore, FIP administration significantly increased testicular malondialdehyde (MDA), pro-inflammatory markers as tumor necrosis factor-α (TNF-α), and interleukin-1β (IL-1β) levels. Also, downregulated the activities of antioxidant markers, Nrf2, HO-1, and PCNA immunostaining. Furthermore, FIP significantly upregulated (p < 0.05) DRP1 and downregulated PGC-1α, MNF2, TFAM, and mtDNA mRNA transcripts. Histopathologically, FIP induced deterioration in seminiferous tubules' histoarchitecture with upregulation in Cosentino's score and downregulation in Johnson's score. On the contrary, TEL effectively restored the testicular function hormones, testicular and epididymal histoarchitecture, antioxidant indices, PGC-1α, and TFAM, with downregulation in MDA levels and DRP1 mRNA transcript. In conclusion, TEL protects the testicular mitochondria against damage from FIP toxicosis by modulating the Nrf2/HO-1/PGC-1α/MNF2/DRP1 expressions.

Two new simple and accurate solvent blends have been presented for the quantification of Telmisartan (TEL) in bulk and its tablet dosage form. The developed analytical method was validated and established in ICH Q2 (R1). Telmisartan exhibit 298 nm and 291 nm for Solvent A, Solvent B respectively and found was linear for a range of 1 µg/ml to 50 µg/ml.The goodness of fit study suggests good correlation coefficient R2 - 0.9989 and 0.999 for proposed solvents. The validity of Beer’s law with intercept response &lt; 2% calculated by the least square method indicating functional linearity between the concentration of analyte and the absorbance. The (LOD) of Telmisartan was found to be 0.07642±0.1224μg/ml and the limit of quantification (LOQ) of Telmisartan was found to be 0.07642±0.1224μg/ml with %RSD &lt; 2.The analytical method validation of proposed solvent blends was performed by carrying out precision and accuracy studies. The Accuracy percentage recovery on three different levels i.e. 50%, 100% and 150% was found to be within the acceptable limits with RSD &lt; 2. The proposed solvent blends were validated for specificity, precision, ruggedness, accuracy and robustness. Overall study suggest that the proposed solvent blends can be used for quantification of Telmisartan in bulk and its tablet dosage form and can be applied for the everyday quality control analysis.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes COVID-19, a respiratory viral infection that disrupts renin angiotensin system (RAS) peptide metabolism by downregulating angiotensin converting enzyme-II (ACE2), leading to accumulation of pro-inflammatory angiotensin II (AngII). We posit that angiotensin receptor blockers (ARBs) like telmisartan (TEM) can activate the pro-resolving arm of RAS (MasR/ACE2/Ang1-7), reducing lung inflammation in COVID-19 patients. In this randomized, double-blinded, placebo-controlled pilot clinical trial, outpatient SARS-CoV-2-infected study participants received either 40mg TEM or placebo once daily. Plasma inflammatory biomarker levels revealed a reduction in global systemic inflammation with TEM treatment, corresponding with an increase in MasR. We corroborated these clinical findings with in vitro analysis. A549-ACE2 lung epithelial cells treated with TEM showed increased ACE2 and MasR, as well as decreased angiotensin II receptor type I (AT1R) and angiotensin II receptor type II (AT2R) expression levels. Additionally, AngII peptide levels decreased, while Ang(1-9) and Ang(1-7) increased. TEM treatment at physiologically achievable concentration reduced SARS-CoV-2 viral load. Taken collectively, these results show TEM mediated activation of the Ang(1-7)/MasR/ACE2 pro-resolving arm of RAS, which activates anti-inflammatory events that reduce global inflammation. These findings support the use of ARBs like TEM in mitigating COVID-19 driven alterations in RAS.

ABSTRACT Metabolically dysfunction-associated steatotic liver disease (MASLD) has emerged as the leading chronic liver disease worldwide, driven primarily by metabolic derangement. The current investigation proposes to elucidate the hepatoprotective mechanisms of telmisartan (TEL) in MASLD. Twenty-four male Wistar rats were allocated to four groups (Control, MASLD, TEL-treated, and MASLD/TEL). Lipid profiles, glycemic markers, liver enzymes, and hepatic markers of oxidative stress (malondialdehyde (MDA), glutathione (GSH), superoxide dismutase (SOD), and catalase) were measured. MASLD-associated genes retrieved from GeneCards® were mapped to Rattus norvegicus ortholog genes using the gprofiler2 R package. Kyoto Encyclopedia of Genes and Genomes (KEGG) and Reactome enrichment analyses were subsequently performed using the clusterProfiler R package. Hepatic inflammatory cytokines (TNF-β, IL-6, and NF-κB), mitochondrial respiratory enzymes (Complexes I–IV), and the gene expression of Nrf2, HO-1, MMP-9, and TIMP-1 were evaluated using spectrophotometric assays for mitochondrial respiratory enzymes. Histological assessment was done using Hematoxylin and Eosin (H&E) staining, Masson's trichrome, and TGF-β immunostaining. TEL ameliorates MASLD-associated disturbances in the serum ALT level and lipid profile. It significantly reduces the levels of oxidative stress markers. KEGG and Reactome enrichment highlighted pathways involved in lipid metabolism, insulin resistance, and inflammation, with the peroxisome proliferator–activated receptor (PPAR) and AMP-activated protein kinase (AMPK) signaling pathways being the most enriched. TEL treatment increased the hepatic expression of Nrf2, HO-1, and TIMP−1 while decreasing the expression of MMP-9. The levels of the proinflammatory cytokines TNF-α and IL-6 decreased. The activities of mitochondrial enzymes (citrate synthase and complex I) improved. MASLD induced marked hepatic fibrosis, which was markedly improved following TEL treatment. TEL has notable hepatoprotective properties in MASLD by enhancing metabolic parameters, decreasing oxidative stress, and moderating inflammatory reactions.

Effective management of hypertension typically involves multiple medications. This underscores the pharmaceutical industry’s demand for simple, cost-effective, and environmentally sustainable analytical methods capable of handling complex, multicomponent formulations. This study’s primary goal was to compare and validate univariate and multivariate spectrophotometric techniques for analyzing fixed-dose antihypertensive formulations of Telmisartan (TEL), Chlorthalidone (CHT), and Amlodipine (AML). Successive Ratio Subtraction paired with Constant Multiplication (SRS-CM) and Successive Derivative Subtraction paired with Constant Multiplication (SDS-CM) were the developed univariate methods. The cited drugs were successfully quantified at their respective maxima: 295.7 nm for TEL, 275.0 nm for CHT, and 359.5 nm for AML. On the other hand, the SDS-CM method enabled their determination using first-derivative spectra, with TEL identified at P282.5–313 nm, CHT at 287.0 nm, and AML at P231-246 nm. Also, Interval-Partial Least Squares (iPLS) and Genetic Algorithm-Partial Least Squares (GA-PLS) were applied as multivariate techniques. In contrast to full-spectrum modeling alone, the results showed that adding variable selection techniques greatly improved the model’s performance. Following ICH guidelines, the proposed techniques were used to quantify the cited medications in tablets. The validity of the results was confirmed by statistical comparison with the reported method. The study was further expanded to assess the content uniformity of the dosage units in compliance with USP. Three environmental complementary assessment tools were employed: the Analytical Greenness Metric (AGREE), the Blue Applicability Grade Index (BAGI) and White Analytical Chemistry (RGB12). This study also aligns with several UN Sustainable Development Goals (UN-SDGs), emphasizing commitment to green pharmaceutical research. Sustainability was verified using the NQS index, confirming the method’s compliance with responsible analytical practices.Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-025-22700-0.

Fixed-dose combination (FDC) of antihypertensive drugs improve efficacy, safety, and patient adherence over monotherapy. However, a FDC of telmisartan (TEL) and indapamide (IND), both poorly soluble BCS Class II drugs, has not been available yet. This study aimed to develop an orodispersible film (ODF) containing TEL and IND cyclodextrin (CD) inclusion complexes (ICs) to enhance solubility and offer a patient adherence dosage form. In the first phase of the study, phase-solubility analysis was performed with β-CD then the ICs were prepared via kneading and assessed for solubility enhancement and entrapment efficiency. In the second phase, ICs were incorporated into hydroxypropyl-methylcellulose (HPMC) based ODFs using solvent casting. The films were characterized for thickness, mass and content uniformity, surface pH, water content, folding endurance, Young’s modulus, FTIR, in vitro disintegration and dissolution. AL-type phase-solubility plots confirmed 1:1 complexation and enhanced solubility by 1.7–4.1 fold, with entrapment efficiency &gt;95%. ICs-loaded ODFs were thin (0.138 mm), uniform in mass (236.39 mg) and content (TEL 97.22%, IND 102.09%), nearly neutral pH, and low in water (2.68%). Mechanical testing showed adequate flexibility and stiffness (100 N.mm⁻² modulus). Disintegration occurred in

From liver to kidney: Telmisartan attenuates NLRP3 inflammasome-driven systemic inflammation and the iNOS/Hsp70 axis partially via the Mas receptor in a hepatic ischemia-reperfusion model.

Diabetic cardiomyopathy (DCM) is a progressive heart disorder associated with diabetes mellitus, leading to structural and functional cardiac abnormalities. The mechanisms responsible include renin-angiotensin-aldosterone (RAAS) activation, inflammation, apoptosis, and metabolic disturbances. Despite well-established epidemiological links, treatments for DCM are elusive. This study evaluated the efficacy of a novel combination of recombinant Klotho (KL) and the angiotensin receptor blocker telmisartan (TEL) in treating DCM, as well as investigating potential mechanisms involved. DCM was induced with a single dose of streptozotocin (55 mg/kg, i.p.), followed by a 4-week induction period. For treatment, rats were assigned to five groups: Normal control (NC), Diabetic control (DC), DC + KL (0.01 mg/kg, S.C.), DC + TEL (10 mg/kg, p.o.), and KL + TEL combination. Plasma biochemistry assessed cardiac damage (LDH, CK-MB) and stress markers (ANP, BNP). Electrocardiogram (ECG) measured heart parameters, including heart rate (HR), QTc, JT interval, RR interval, and Tpeak-Tend intervals. Histological analysis (H&E, Masson's trichrome, and Picrosirius red) was performed to assess myocardial structure and fibrosis. Lastly, immunohistochemistry analysis was performed to check the expression of transforming growth factor-β1 (TGF-β1), pSMAD 2/3, matrix metalloproteinase 9 (MMP9), and PRKN. KL and TEL combination treatment significantly reduced cardiac damage markers, reduced ECG abnormalities, including QTc, improved HR while suppressing pro-fibrotic signaling, enhancing mitophagy, and decreasing fibroblast proliferation. The involvement of pathways involving TGF-β1, pSMAD-2/3, MMP9, and pFOXO3a conferred protection to the heart in experimental in-vivo settings. These findings suggest that the combination of KL and TEL effectively mitigates key pathological features of DCM, highlighting its potential as a targeted treatment strategy.

Effects of chronic stress and angiotensin II type 1 receptor blockade on rats' performance in the five-choice serial reaction time task (5-CSRTT).

Abstract ObjectivesWhen formulating new strategies, contemporary analysts prioritize sustainability. Research in green analytical chemistry aims to replace hazardous reagents with eco-friendly alternatives and minimize waste generation. This study employed a comprehensive assessment of greenness evaluation tools. A newly validated RP-HPLC method was subsequently applied for the quantitative analysis of Telmisartan (TEL) and Atorvastatin calcium (ATV Ca) in both pure form and tablet formulation.MethodsThe analysis utilized an HPLC-UV Youngling Acme 9000 system with an Inertsil ODS RP column (250 × 4.6 mm, 5 μm), operating at 250 nm. The mobile phase, a 60:40 (v/v) blend of acetonitrile and phosphate buffer (pH 3.5), was delivered at 1.50 mL min−1 under isocratic conditions. Telmisartan (TEL) and Atorvastatin calcium (ATV Ca) showed retention times of 2.75 and 5.33 min, respectively.ResultsCalibration curves were developed to evaluate the linearity of TEL (10–100 μg mL−1) and ATV Ca (2.5–25 μg mL−1), showing a high R2 of 0.999. The LOD and LOQ for TEL were 0.41 μg mL−1 and 0.23 μg mL−1, while for ATV Ca, they were 1.246 μg mL−1 and 0.695 μg mL−1, with recoveries averaging 98.59%–99.95% and 99.57%–99.98%, respectively. Validation of the method was performed following ICH guidelines. Moreover, the greenness assessment of the HPLC method was assessed using the AES, NEMI, AGP, AGREE, ComplexMoGAPI, AMGS, and BAGI.ConclusionThis study validates the newly developed method and evaluates its environmental impact with multiple evaluation tools, confirming its eco-friendly nature, highlighting its potential as a responsible choice for analysing the mixture, especially in quality control labs and the pharmaceutical industry.

Objectives This study aimed to develop and optimize telmisartan (TLS)-curcumin (Cur) solid dispersion nanoparticles (SDNs) to improve the management of diabetic nephropathy (DN) by enhancing TLS’s solubility and release rate. Methods A Box–Behnken design (BBD) was used to optimize the formulation with critical excipients PVP VA S630 and Poloxamer 407. Pre-formulation studies assessed TLS’s solubility and lipophilic nature. The optimized formulation (TLS-15) was evaluated for solubility, drug release, particle size, zeta potential, and in vitro release. A comparison was made with a formulation without Cur (TLS-15 WC). TEM imaging and release kinetics analysis were conducted. Results The optimized formulation (TLS-15) demonstrated significantly improved solubility (4.801 μg/mL) and drug release (99.68%) with an appropriate particle size (303.5 nm) and zeta potential (−12.17 mV). TLS-15 WC exhibited lower values for solubility (4.74 μg/mL), drug release (98.3%), particle size (291.2 nm), and zeta potential (−25.4 mV). TEM revealed uniformly distributed spherical nanoparticles (NPs). TLS-15 showed a 99.54% release after 6 h, compared to 98.3% for TLS-15 WC, following first-order release kinetics (R 2 = 0.9934). Conclusions The study successfully developed and optimized TLS-Cur SDNs, enhancing TLS’s solubility and release. Cur played a critical role in boosting the therapeutic potential of the formulation. While challenges remain with stability and manufacturing, the formulation shows promise for improving bioavailability and efficacy in DN treatment. However, additional studies are needed to validate its effectiveness.

Hypertension-induced renal injury arises from endothelial dysfunction and elevated glomerular permeability. Telmisartan, an Angiotensin II (Ang II) receptor blocker (ARB), is commonly used to treat hypertension and is known for its long-lasting effects, as well as its antioxidant and anti-inflammatory properties. However, the effects of Telmisartan on glomerular permeability are less well-documented. This study investigates the protective effects of Telmisartan (TEL), an Ang II receptor blocker, on hypertension-induced kidney damage. Using a mouse model of Angiotensin II/high salt (ANG/HS)-induced hypertension, TEL treatment significantly reduced mean arterial pressure, alleviated renal fibrosis, and improved kidney function, as indicated by lower urinary albumin and serum creatinine levels. TEL also suppressed oxidative stress and reduced the expression of inflammatory markers interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) in renal tissues. Furthermore, TEL restored the expression of the tight junction protein zonula occludens-1 (ZO-1) in the glomeruli, which was downregulated in ANG/HS-treated mice. In vitro studies on human renal glomerular endothelial cells (HrGECs) confirmed that TEL reduced endothelial monolayer permeability and restored ZO-1 expression, effects that were mediated by Krüppel-like factor 4 (KLF4). These findings suggest that TEL mitigates glomerular endothelial permeability and kidney damage through antioxidant, anti-inflammatory, and KLF4-dependent mechanisms, offering potential therapeutic benefits for hypertension-related renal damage.

ABSTRACT: The primary goal of this work was to create and test a stability-indicating reverse-phase high-performance liquid chromatography (RP-HPLC) method for the simultaneous detection of telmisartan (TEL) and benidipine hydrochloride (BEN) in bulk and pharmaceutical dose form. Using reverse phase chromatography, the developed method is simple, appropriate, and more efficient, stable, and reproducible. The C18 column, measuring 250 x 4.6 mm and packed with 5.0 μm particles, was used to separate TEL and BEN. When used as a mobile phase, various solvent solutions were evaluated and improved. TEL (100 μg/ml) and BEN (10 μg/ml) were used for their good peak forms and resolution in Methanol: Ammonium Dihydrogen Orthophosphate Buffer, pH 3.5 (80:20 v/v). The mobile phase was flowing at 1.0 ml/min, and both analytes were detected at 237 nm using UV/ Vis detectors. The method's development and validation were based on linearity, accuracy, precision, robustness, specificity, linearity, detection limit, and quantitation limit. TEL and BEN were found to be linear at doses of 5-15 and 50-150 μg/ml. According to this study, the impact of RP-HPLC techniques included a reduction of sample quality and standardization. The fact that the percentage relative standard deviation was less than 2% proved the exceptional precision of the proposed procedure.

The anti-atherosclerotic effect of chronic AT1 receptor blocker treatment also depends on the ACE2/Ang(1-7)/Mas axis.

The main purpose of this study was to design and develop a solid self-nanoemulsifying drug delivery system (S-SNEDDS) for the oral administration of benidipine (BD) and telmisartan (TEL) using the adsorption method with eucalyptus oil, Transcutol P, and Kolliphor EL via the Box-Behnken design approach. The prepared SNEDDS formulations were characterized using FTIR, DSC, SEM, and PXRD techniques and evaluated for zeta potential, refractive index, drug concentration, resistance to dilution, viscosity, and thermodynamic stability. Additionally, in vitro and stability studies were conducted. The results revealed that all prepared formulations (BT1-BT15) exhibited favorable zeta potential (17.2-28.39 mV) and polydispersity index (PDI) values (0.226-0.354). Among them, formulation BT11 demonstrated a desirable droplet size of 175.12 ± 2.70 nm, a PDI of 0.226, a zeta potential of -24.98 ± 0.18 mV, a self-emulsification time of 53.00 ± 2.10 s, a transmittance percentage of 99.6 ± 0.3%, and a drug release of 92.65 ± 1.70% within 15 min. BT11 exhibited significantly faster drug release compared to the commercially available product benidipine T (4 mg/40 mg) and the pure drugs BD and TEL, releasing more than 96% of both drugs in 0.1 N HCl within 60 min. Furthermore, BT11 demonstrated stability throughout the product's stability testing. These findings suggest that the oral S-SNEDDS formulation of BD and TEL can enhance the drugs' water solubility, potentially improving therapeutic outcomes and increasing patient compliance.

The selection of IR spectroscopic approach for quantification of drugs supports green analytical chemistry principles without compromising the method analytical performance. The method follows pressed pellet technique for preparing samples using potassium bromide without using any toxic solvents and even reduced waste too. An easy, fast, and environmentally friendly FT-IR spectrophotometric method was developed and validated for the simultaneous measurement of amlodipine besylate (AML) and telmisartan (TEL) in pharmaceutical combination formulations. The absorbance spectra which was obtained from obtained transmittance spectra were used for determining area under curve and correlated with amount or concentration. AML and TEL shows peaks at 1206 cm− 1 and 863 cm− 1. Validation of the developed method followed ICH guidelines and all the validation results were within the limits. The LOD and LOQ of AML were found as 0.009359 %w/w, 0.028359 %w/w respectively where for TEL it was found to be 0.008241 %w/w and 0.024974 %w/w respectively. The MoGAPI, AGREE prep, and RGB model assessment procedure was green and sustainable. The described HPLC technique was not significantly different statistically.

Cardiovascular diseases are the major cause of global mortality, and often require the concomitant use of a number of drugs to prevent and reduce these deaths. The challenge is to find effective and accurate methods for analyzing these drugs in plasma. This research introduces an innovative, sustainable HPLC-FLD method for the concurrent determination of bisoprolol (BIS), amlodipine besylate (AML), telmisartan (TEL), and atorvastatin (ATV) within human plasma. Chromatographic separation was achieved using an isocratic elution mode on a Thermo Hypersil BDS C18 column (150 × 4.6 mm, 5.0 μm), while the mobile phase comprised of ethanol and 0.03 M potassium phosphate buffer (pH 5.2) in a 40:60 ratio, with a flow rate of 0.6 mL/min. The eluate was analyzed using UV detection within the wavelength range of 210–260 nm to confirm effective separation of the four cardiovascular drugs. For enhanced specificity, a fluorescence detector was set to 227ex/298em for BIS, 294ex/365em for TEL, 274ex/378em for ATV, and 361ex/442em for amlodipine. The method was validated following the International Council for Harmonisation (ICH) guidelines. Linearity was established within the ranges of 5–100 ng/mL for BIS and AML, 0.1–5 ng/mL for TEL, and 10–200 ng/mL for ATV, ensuring accuracy and precision. The significant of the current work represented in introduction of a highly sensitive, and selective analytical method, utilizing an economical sample preparation strategy, for the simultaneous determination of four different cardiovascular drugs (bisoprolol, amlodipine, telmisartan, and atorvastatin) in spiked human plasma. The extraction of sample was carried by liquid-liquid extraction (LLE) and analyzed by LC-fluorescence detector. The chromatographic run was short (less than10 min) which is a greet economical value.